Addressing high risk AML, we at the ALWP conducted a retrospective analysis to determine the clinical outcomes of AML patients undergoing HSCT with respect to specific recurring cytogenetic abnormalities complemented with FLT3-ITD status. This evidence concerns the gene FLT3 and acute myeloid leukemia.